Understanding the Impact of Nail Disorders on Dermatology Patients' Quality of Life
Keywords:
Nail disorders, Quality of life (HRQOL), Dermatology, Nail dystrophy, Onychomycosis
Abstract
Nail disorders significantly impact the quality of life for dermatology patients, particularly due to the prolonged duration of these conditions. This study aims to assess the clinical impact of nail disorders, such as onychomycosis and nail dystrophy, on the health-related quality of life (HRQoL) of dermatology patients. Data were collected from 84 patients, aged 30 to 65, with nail disorders in hospitals in Al-Najaf, Iraq, between April 2023 and August 2024. Using questionnaires like Skindex-29 and the General Health Questionnaire, the study examined the emotional, physical, and social aspects of patients' well-being. Results showed that 69.05% of cases were female, with onychomycosis (55 cases) and nail dystrophy (29 cases) as the primary conditions. Patients with nail dystrophy had more severe symptoms and lower social functioning compared to those with onychomycosis. In general health assessments, patients with nail dystrophy also reported slightly lower overall well-being. The findings highlight the importance of addressing both physical and emotional aspects in treating nail disorders to improve patients' quality of life.
References
[1] I.J. Higginson and A.J. Carr, "Measuring Quality of Life: Using Quality of Life Measures in the Clinical Setting," BMJ, vol. 322, pp. 1297–1300, 2001.
[2] K.N. Lohr, "Advances in Health Status Assessment: Overview of the Conference," Med Care, vol. 27, pp. S1–S11, 1989.
[3] K.N. Lohr, "Applications of Health Status Assessment Measures in Clinical Practice: Overview of the Third Conference on Advances in Health Status Assessment," Med Care, vol. 30, pp. MS1–MS14, 1992.
[4] A. Bowling, Ed., Measuring Disease. Buckingham: Open University Press, 1995.
[5] R.M. Rosser, "A History of the Development of Health Indices," in G.T. Smith, Ed., Measuring the Social Benefits of Medicine. London: Office of Health Economics, 1985.
[6] M.M. Chren, R.J. Lasek, S.A. Flocke, and S.J. Zyzanski, "Improved Discriminative and Evaluative Capability of a Refined Version of Skindex, a Quality-of-Life Instrument for Patients with Skin Diseases," Arch Dermatol, vol. 133, pp. 1433–1440, 1997.
[7] D. Abeni, A. Picardi, P. Puddu, P. Pasquini, and M.M. Chren, "Construction and Validation of the Italian Version of Skindex-29, a New Instrument to Measure Quality of Life in Dermatology [in Italian, abstract in English]," G Ital Dermatol Venereol, vol. 136, pp. 73–76, 2001.
[8] D. Abeni, A. Picardi, P. Pasquini, C.F. Melchi, and M.M. Chren, "Further Evidence of the Validity and Reliability of the Skindex-29: An Italian Study on 2242 Dermatological Outpatients," Dermatology, vol. 204, pp. 43–49, 2002.
[9] M. Piccinelli, G. Bisoffi, M.G. Bon, L. Cunico, and M. Tansella, "Validity and Test-Retest Reliability of the Italian Version of the 12-Item General Health Questionnaire in General Practice: A Comparison Between Three Scoring Methods," Compr Psychiatry, vol. 34, pp. 198–205, 1993.
[10] A. Picardi, D. Abeni, and P. Pasquini, "Assessing Psychological Distress in Patients with Skin Diseases: Reliability, Validity and Factor Structure of the GHQ-12," J Eur Acad Dermatol Venereol, vol. 15, pp. 410–417, 2001.
[11] A. Picardi, D. Abeni, E. Mazzotti, G. Fassone, I. Lega, L. Ramieri, et al., "Screening for Psychiatric Disorders in Patients with Skin Diseases: A Performance Study of the 12-Item General Health Questionnaire (GHQ-12)," J Psychosom Res, vol. 57, pp. 219–223, 2004.
[12] U.S. Food and Drug Administration, "Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims," 2009. [Online]. Available: https://www.fda.gov/media/77832/download. [Accessed: Oct. 14, 2023].
[13] C.F. Snyder, N. Crossnohere, M. King, et al., "The PROTEUS-Trials Consortium: Optimizing the Use of Patient-Reported Outcomes in Clinical Trials," Clin Trials, vol. 19, no. 3, pp. 277–284, 2022. doi: 10.1177/17407745221077691.
[14] M. Calvert, D. Kyte, G. Price, et al., "Maximising the Impact of Patient-Reported Outcome Assessment for Patients and Society," BMJ, vol. 364, 2019.
[15] C.F. Snyder, N.K. Aaronson, A.K. Choucair, et al., "Implementing Patient-Reported Outcomes Assessment in Clinical Practice: A Review of the Options and Considerations," Qual Life Res, vol. 21, no. 8, pp. 1305–1314, 2012.
[16] C. Gibbons, I. Porter, D.C. Gonçalves-Bradley, et al., "Routine Provision of Feedback from Patient-Reported Outcome Measurements to Healthcare Providers and Patients in Clinical Practice," Cochrane Database Syst Rev, vol. 2021, no. 10, 2021.
[17] K. Maruszczyk, O.L. Aiyegbusi, B. Torlinska, et al., "Systematic Review of Guidance for the Collection and Use of Patient-Reported Outcomes in Real-World Evidence Generation to Support Regulation, Reimbursement, and Health Policy," J Patient Rep Outcomes, vol. 6, no. 1, pp. 1–11, 2022. doi: 10.1186/s41687-022-00466-7.
[18] L. Squitieri, K.J. Bozic, A.L. Pusic, "The Role of Patient-Reported Outcome Measures in Value-Based Payment Reform," Value Health, vol. 20, no. 6, pp. 834–836, 2017. doi: 10.1016/j.jval.2017.02.003.
[19] L.A. Drake, D.L. Patrick, P. Fleckman, et al., "The Impact of Onychomycosis on Quality of Life: Development of an International Onychomycosis-Specific Questionnaire to Measure Patient Quality of Life," J Am Acad Dermatol, vol. 41, no. 2, pp. 189–196, 1999. doi: 10.1016/s0190-9622(99)70047-2.
[20] D.P. Lubeck, D. Gause, J.R. Schein, et al., "A Health-Related Quality of Life Measure for Use in Patients with Onychomycosis: A Validation Study," Qual Life Res, vol. 8, no. 1, pp. 121–129, 1999. doi: 10.1023/a:1026429012353.
[21] R.R. Turner and M.A. Testa, "Measuring the Impact of Onychomycosis on Patient Quality of Life," Qual Life Res, vol. 9, no. 1, pp. 39–53, 2000. doi: 10.1023/a:1026429012353.
[22] E.M. Warshaw, J.K. Foster, P.M. Cham, et al., "NailQoL: A Quality-of-Life Instrument for Onychomycosis," Int J Dermatol, vol. 46, no. 12, pp. 1279–1286, 2007. doi: 10.1111/j.1365-4632.2007.03362.x.
[23] L.P. Potter, S.D. Mathias, M. Raut, et al., "The OnyCOE-t™ Questionnaire: Responsiveness and Clinical Meaningfulness of a Patient-Reported Outcomes Questionnaire for Toenail Onychomycosis," Health Qual Life Outcomes, vol. 4, no. 1, pp. 1–8, 2006. doi: 10.1186/1477-7525-4-50.
[24] J.P. Ortonne, R. Baran, M. Corvest, et al., "Development and Validation of Nail Psoriasis Quality of Life Scale (NPQ10)," J Eur Acad Dermatol Venereol, vol. 24, no. 1, pp. 22–27, 2010. doi: 10.1111/j.1468-3083.2009.03344.x.
[25] M. Augustin, C. Blome, A. Costanzo, et al., "Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): Development and Validation of a Tool for Assessment of Nail Psoriasis Outcomes," Br J Dermatol, vol. 170, no. 3, pp. 591–598, 2014. doi: 10.1111/bjd.12664.
[26] C.A.D. Prinsen, L.B. Mokkink, L.M. Bouter, et al., "COSMIN Guideline for Systematic Reviews of Patient-Reported Outcome Measures," Qual Life Res, vol. 27, no. 5, pp. 1147–1157, 2018. doi: 10.1007/s11136-018-1798-3.
[27] C.B. Terwee, C.A. Prinsen, A. Chiarotto, et al., "COSMIN Methodology for Evaluating the Content Validity of Patient-Reported Outcome Measures: A Delphi Study," Qual Life Res, vol. 27, no. 5, pp. 1159–1170, 2018. doi: 10.1007/s11136-018-1829-0.
[28] R. Kamran, L. Algu, C.F. Leveille, et al., "Patient-Reported Outcome Measures for Patients with Nail Conditions: A Systematic Review of the Psychometric Evidence," Arch Dermatol Res, vol. 314, no. 3, pp. 223–237, 2022. doi: 10.1007/s00403-021-02222-1.
[29] G. Rasch, Studies in Mathematical Psychology: 1. Probabilistic Models for Some Intelligence and Attainment Tests. Copenhagen, Denmark: Danmarks Pædagogiske Institut, 1960.
[30] J. Hobart and S. Cano, "Improving the Evaluation of Therapeutic Interventions in Multiple Sclerosis: The Role of New Psychometric Methods," Health Technol Assess, vol. 13, pp. 177, 2009. doi: 10.3310/hta13120.
[31] A. Regnault, T. Willgoss, S. Barbic, and the International Society for Quality-of-Life Research Mixed Methods Special Interest Group, "Towards the Use of Mixed Methods Inquiry as Best Practice in Health Outcomes Research," J Patient Rep Outcomes, vol. 2, no. 1, pp. 1–4, 2018. doi: 10.1186/s41687-018-0043-8.
[32] S. Thorne, S.R. Kirkham, and J. MacDonald-Emes, "Interpretive Description: A Noncategorical Qualitative Alternative for Developing Nursing Knowledge," Res Nurs Health, vol. 20, no. 2, pp. 169–177, 1997. doi: 10.1002/(SICI)1098-240X(199704)20:2<169::AID-RNH6>3.0.CO;2-I.
[33] C. Pope, S. Ziebland, and N. Mays, "Qualitative Research in Health Care: Analysing Qualitative Data," Br Med J, vol. 320, no. 7227, pp. 114–116, 2000. doi: 10.1136/bmj.320.7227.114.
[34] M. Sandelowski, "Theoretical Saturation," in The Sage Encyclopedia of Qualitative Methods, L.M. Given, Ed. Thousand Oaks, CA: Sage, vol. 1, pp. 875–876, 2008.
[35] G.B. Willis, Cognitive Interviewing in Practice: Think-Aloud, Verbal Probing, and Other Techniques: Cognitive Interviewing. Thousand Oaks: Sage Publications, 2005, pp. 42–65.
[2] K.N. Lohr, "Advances in Health Status Assessment: Overview of the Conference," Med Care, vol. 27, pp. S1–S11, 1989.
[3] K.N. Lohr, "Applications of Health Status Assessment Measures in Clinical Practice: Overview of the Third Conference on Advances in Health Status Assessment," Med Care, vol. 30, pp. MS1–MS14, 1992.
[4] A. Bowling, Ed., Measuring Disease. Buckingham: Open University Press, 1995.
[5] R.M. Rosser, "A History of the Development of Health Indices," in G.T. Smith, Ed., Measuring the Social Benefits of Medicine. London: Office of Health Economics, 1985.
[6] M.M. Chren, R.J. Lasek, S.A. Flocke, and S.J. Zyzanski, "Improved Discriminative and Evaluative Capability of a Refined Version of Skindex, a Quality-of-Life Instrument for Patients with Skin Diseases," Arch Dermatol, vol. 133, pp. 1433–1440, 1997.
[7] D. Abeni, A. Picardi, P. Puddu, P. Pasquini, and M.M. Chren, "Construction and Validation of the Italian Version of Skindex-29, a New Instrument to Measure Quality of Life in Dermatology [in Italian, abstract in English]," G Ital Dermatol Venereol, vol. 136, pp. 73–76, 2001.
[8] D. Abeni, A. Picardi, P. Pasquini, C.F. Melchi, and M.M. Chren, "Further Evidence of the Validity and Reliability of the Skindex-29: An Italian Study on 2242 Dermatological Outpatients," Dermatology, vol. 204, pp. 43–49, 2002.
[9] M. Piccinelli, G. Bisoffi, M.G. Bon, L. Cunico, and M. Tansella, "Validity and Test-Retest Reliability of the Italian Version of the 12-Item General Health Questionnaire in General Practice: A Comparison Between Three Scoring Methods," Compr Psychiatry, vol. 34, pp. 198–205, 1993.
[10] A. Picardi, D. Abeni, and P. Pasquini, "Assessing Psychological Distress in Patients with Skin Diseases: Reliability, Validity and Factor Structure of the GHQ-12," J Eur Acad Dermatol Venereol, vol. 15, pp. 410–417, 2001.
[11] A. Picardi, D. Abeni, E. Mazzotti, G. Fassone, I. Lega, L. Ramieri, et al., "Screening for Psychiatric Disorders in Patients with Skin Diseases: A Performance Study of the 12-Item General Health Questionnaire (GHQ-12)," J Psychosom Res, vol. 57, pp. 219–223, 2004.
[12] U.S. Food and Drug Administration, "Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims," 2009. [Online]. Available: https://www.fda.gov/media/77832/download. [Accessed: Oct. 14, 2023].
[13] C.F. Snyder, N. Crossnohere, M. King, et al., "The PROTEUS-Trials Consortium: Optimizing the Use of Patient-Reported Outcomes in Clinical Trials," Clin Trials, vol. 19, no. 3, pp. 277–284, 2022. doi: 10.1177/17407745221077691.
[14] M. Calvert, D. Kyte, G. Price, et al., "Maximising the Impact of Patient-Reported Outcome Assessment for Patients and Society," BMJ, vol. 364, 2019.
[15] C.F. Snyder, N.K. Aaronson, A.K. Choucair, et al., "Implementing Patient-Reported Outcomes Assessment in Clinical Practice: A Review of the Options and Considerations," Qual Life Res, vol. 21, no. 8, pp. 1305–1314, 2012.
[16] C. Gibbons, I. Porter, D.C. Gonçalves-Bradley, et al., "Routine Provision of Feedback from Patient-Reported Outcome Measurements to Healthcare Providers and Patients in Clinical Practice," Cochrane Database Syst Rev, vol. 2021, no. 10, 2021.
[17] K. Maruszczyk, O.L. Aiyegbusi, B. Torlinska, et al., "Systematic Review of Guidance for the Collection and Use of Patient-Reported Outcomes in Real-World Evidence Generation to Support Regulation, Reimbursement, and Health Policy," J Patient Rep Outcomes, vol. 6, no. 1, pp. 1–11, 2022. doi: 10.1186/s41687-022-00466-7.
[18] L. Squitieri, K.J. Bozic, A.L. Pusic, "The Role of Patient-Reported Outcome Measures in Value-Based Payment Reform," Value Health, vol. 20, no. 6, pp. 834–836, 2017. doi: 10.1016/j.jval.2017.02.003.
[19] L.A. Drake, D.L. Patrick, P. Fleckman, et al., "The Impact of Onychomycosis on Quality of Life: Development of an International Onychomycosis-Specific Questionnaire to Measure Patient Quality of Life," J Am Acad Dermatol, vol. 41, no. 2, pp. 189–196, 1999. doi: 10.1016/s0190-9622(99)70047-2.
[20] D.P. Lubeck, D. Gause, J.R. Schein, et al., "A Health-Related Quality of Life Measure for Use in Patients with Onychomycosis: A Validation Study," Qual Life Res, vol. 8, no. 1, pp. 121–129, 1999. doi: 10.1023/a:1026429012353.
[21] R.R. Turner and M.A. Testa, "Measuring the Impact of Onychomycosis on Patient Quality of Life," Qual Life Res, vol. 9, no. 1, pp. 39–53, 2000. doi: 10.1023/a:1026429012353.
[22] E.M. Warshaw, J.K. Foster, P.M. Cham, et al., "NailQoL: A Quality-of-Life Instrument for Onychomycosis," Int J Dermatol, vol. 46, no. 12, pp. 1279–1286, 2007. doi: 10.1111/j.1365-4632.2007.03362.x.
[23] L.P. Potter, S.D. Mathias, M. Raut, et al., "The OnyCOE-t™ Questionnaire: Responsiveness and Clinical Meaningfulness of a Patient-Reported Outcomes Questionnaire for Toenail Onychomycosis," Health Qual Life Outcomes, vol. 4, no. 1, pp. 1–8, 2006. doi: 10.1186/1477-7525-4-50.
[24] J.P. Ortonne, R. Baran, M. Corvest, et al., "Development and Validation of Nail Psoriasis Quality of Life Scale (NPQ10)," J Eur Acad Dermatol Venereol, vol. 24, no. 1, pp. 22–27, 2010. doi: 10.1111/j.1468-3083.2009.03344.x.
[25] M. Augustin, C. Blome, A. Costanzo, et al., "Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): Development and Validation of a Tool for Assessment of Nail Psoriasis Outcomes," Br J Dermatol, vol. 170, no. 3, pp. 591–598, 2014. doi: 10.1111/bjd.12664.
[26] C.A.D. Prinsen, L.B. Mokkink, L.M. Bouter, et al., "COSMIN Guideline for Systematic Reviews of Patient-Reported Outcome Measures," Qual Life Res, vol. 27, no. 5, pp. 1147–1157, 2018. doi: 10.1007/s11136-018-1798-3.
[27] C.B. Terwee, C.A. Prinsen, A. Chiarotto, et al., "COSMIN Methodology for Evaluating the Content Validity of Patient-Reported Outcome Measures: A Delphi Study," Qual Life Res, vol. 27, no. 5, pp. 1159–1170, 2018. doi: 10.1007/s11136-018-1829-0.
[28] R. Kamran, L. Algu, C.F. Leveille, et al., "Patient-Reported Outcome Measures for Patients with Nail Conditions: A Systematic Review of the Psychometric Evidence," Arch Dermatol Res, vol. 314, no. 3, pp. 223–237, 2022. doi: 10.1007/s00403-021-02222-1.
[29] G. Rasch, Studies in Mathematical Psychology: 1. Probabilistic Models for Some Intelligence and Attainment Tests. Copenhagen, Denmark: Danmarks Pædagogiske Institut, 1960.
[30] J. Hobart and S. Cano, "Improving the Evaluation of Therapeutic Interventions in Multiple Sclerosis: The Role of New Psychometric Methods," Health Technol Assess, vol. 13, pp. 177, 2009. doi: 10.3310/hta13120.
[31] A. Regnault, T. Willgoss, S. Barbic, and the International Society for Quality-of-Life Research Mixed Methods Special Interest Group, "Towards the Use of Mixed Methods Inquiry as Best Practice in Health Outcomes Research," J Patient Rep Outcomes, vol. 2, no. 1, pp. 1–4, 2018. doi: 10.1186/s41687-018-0043-8.
[32] S. Thorne, S.R. Kirkham, and J. MacDonald-Emes, "Interpretive Description: A Noncategorical Qualitative Alternative for Developing Nursing Knowledge," Res Nurs Health, vol. 20, no. 2, pp. 169–177, 1997. doi: 10.1002/(SICI)1098-240X(199704)20:2<169::AID-RNH6>3.0.CO;2-I.
[33] C. Pope, S. Ziebland, and N. Mays, "Qualitative Research in Health Care: Analysing Qualitative Data," Br Med J, vol. 320, no. 7227, pp. 114–116, 2000. doi: 10.1136/bmj.320.7227.114.
[34] M. Sandelowski, "Theoretical Saturation," in The Sage Encyclopedia of Qualitative Methods, L.M. Given, Ed. Thousand Oaks, CA: Sage, vol. 1, pp. 875–876, 2008.
[35] G.B. Willis, Cognitive Interviewing in Practice: Think-Aloud, Verbal Probing, and Other Techniques: Cognitive Interviewing. Thousand Oaks: Sage Publications, 2005, pp. 42–65.
Published
2024-09-10
How to Cite
Abbas , O. R. (2024). Understanding the Impact of Nail Disorders on Dermatology Patients’ Quality of Life. Central Asian Journal of Medical and Natural Science, 5(4), 754-765. Retrieved from https://cajmns.centralasianstudies.org/index.php/CAJMNS/article/view/2606
Section
Articles
This work is licensed under a Creative Commons Attribution 4.0 International License.
